No lost causes at Xilio and Lyell
The companies press on with vilastobart and IMPT-314... up to a point.
Xilio's second bailout
AbbVie follows Gilead in throwing Xilio a lifeline.
ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Xilio gets a Gilead-shaped reprieve
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
SITC 2023 – Aulos and Xilio press on with cytokine approaches
But the groups have yet to see any responses with AU-007 and XTX202 respectively.
